

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.*

WORLD HEALTH ORGANIZATION  
TECHNICAL REPORT SERIES

No. 594

**WHO EXPERT COMMITTEE  
ON BIOLOGICAL  
STANDARDIZATION**

**Twenty-seventh Report**

WORLD HEALTH ORGANIZATION

GENEVA

1976

ISBN 92 4 120594 6

© World Health Organization 1976

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

# CONTENTS

	Page
<b>General</b> . . . . .	7
SUBSTANCES	
<b>Antibiotics</b>	
1. Doxycycline . . . . .	8
2. Neomycin . . . . .	8
3. Candicidin . . . . .	9
4. Trichomycin . . . . .	9
5. Minocycline . . . . .	10
6. Virginiamycin . . . . .	10
7. Bleomycin . . . . .	10
8. Tetracycline and oxytetracycline . . . . .	11
9. Spectinomycin . . . . .	11
10. Tobramycin . . . . .	12
11. Antibiotic sensitivity (susceptibility) discs . . . . .	12
<b>Blood products</b>	
12. Human thrombin . . . . .	12
<b>Antigens</b>	
13. Carcinoembryonic antigen . . . . .	13
14. Alphafetoprotein . . . . .	14
15. <i>Clostridium welchii</i> ( <i>C. perfringens</i> ) beta and epsilon toxoids . . . . .	14
16. Diphtheria toxoid, plain . . . . .	15
17. Diphtheria toxoid, adsorbed . . . . .	15
18. Purified protein derivative of bovine tuberculin . . . . .	15
19. <i>Clostridium botulinum</i> type B toxin . . . . .	16
<b>Miscellaneous substances</b>	
20. International Reference Preparation of Opacity . . . . .	16
<b>Antibodies</b>	
21. Anti-D immunoglobulin . . . . .	17
22. Anti- <i>Echinococcus</i> human serum . . . . .	17
23. Anti- <i>Brucella abortus</i> serum . . . . .	18
REQUIREMENTS FOR BIOLOGICAL SUBSTANCES	
24. Requirements for Yellow Fever Vaccine . . . . .	18
25. Requirements for Meningococcal Polysaccharide Vaccine . . . . .	19
26. Specifications of tests used in the Requirements for <i>Brucella abortus</i> Strain 19 Vaccine (Live—for Veterinary Use) . . . . .	19
27. Requirements for <i>Brucella melitensis</i> Strain Rev. 1 Vaccine (Live—for veterinary use) . . . . .	20
	3

	Page
28. Requirements for Rickettsial Products . . . . .	20
29. Requirements for Rubella Vaccine . . . . .	20
MISCELLANEOUS	
30. Manuals . . . . .	21
31. Human blood products and related substances . . . . .	21
32. List of biological substances . . . . .	21
ANNEXES	
Annex 1. Requirements for Yellow Fever Vaccine (revised 1975) . . . .	23
Annex 2. Requirements for Meningococcal Polysaccharide Vaccine . . . .	50
Annex 3. Specifications of tests used in the Requirements for <i>Brucella abortus</i> Strain 19 Vaccine (Live—for Veterinary Use) : Addendum 1975 .	76
Annex 4. Requirements for biological substances and other sets of recom- mendations . . . . .	83
Annex 5. International standards and international reference preparations .	86

## WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 2-8 December 1975

### Members : \*

- Mr Chou Hai-chun, Deputy Director of the Revolutionary Committee of the Peking Institute for the Control of Pharmaceutical and Biological Products, Peking, China
- Dr H. H. Cohen, Director, National Institute of Public Health, Bilthoven, Netherlands (*Chairman*)
- Professor S. G. Dzagurov, Director, Tarasevič State Institute for the Standardization and Control of Medical Biological Preparations, Moscow, USSR
- Professor D. G. Evans, Director, National Institute for Biological Standards and Control, London, England
- Dr L. Higy-Mandić, Chief, Department of Biological Standardization, Institute of Immunology, Zagreb, Yugoslavia (*Rapporteur*)
- Mr J. Lyng, Department of Biological Standardization, State Serum Institute, Copenhagen, Denmark
- Dr Harry M. Meyer, Jr., Director, Bureau of Biologics, Food and Drug Administration, Bethesda, MD, USA
- Dr H. Mirchamsy, Associate Director, Razi State Institute of Serum and Vaccine Production, Karaj, Iran
- Dr R. Murata, Director, Second Department of Bacteriology, National Institute of Health, Tokyo, Japan (*Vice-Chairman*)
- Dr J. B. Shrivastav, Director General of Health Services, Ministry of Health, New Delhi, India

### Secretariat :

- Mr I. Davidson, Head, Biological Products and Standards Department, Central Veterinary Laboratory, New Haw, Weybridge, Surrey, England (*Consultant*)
- Dr J. W. Lightbown, Head, Division of Antibiotics, National Institute for Biological Standards and Control, London, England (*Consultant*)
- Dr F. T. Perkins, Chief, Biological Standardization, WHO, Geneva, Switzerland (*Secretary*)
- Dr J. Spaander, Director-General, National Institute of Public Health, Bilthoven, Netherlands (*Consultant*)
- Mr Tsou Pang-chu, Chief, Vaccine Section, Peking Institute for the Control of Pharmaceutical and Biological Products, Peking, China (*Consultant*)
- Dr W. W. Wright, Deputy Associate Director, Pharmaceutical Research and Testing, Bureau of Drugs, Food and Drug Administration, Washington, DC, USA (*Consultant*)

---

\* Unable to attend : Dr E. C. Gotschlich, Associate Professor and Physician, The Rockefeller University, New York, NY, USA ; Dr J. Spaun, Director, Department of Biological Standardization, State Serum Institute, Copenhagen, Denmark.



# **WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION**

## **Twenty-seventh Report**

The WHO Expert Committee on Biological Standardization met in Geneva from 2 to 8 December 1975. The meeting was opened on behalf of the Director-General by Dr D. Tejada-de-Rivero, Assistant Director-General, who spoke of the emphasis that was now being placed on the application of standards and of the increased use of the biological standardization programme in a more practical way, especially in the developing countries. He asked the Committee to pay particular attention to the type of meetings needed in the future and to consider whether the format used at the twenty-sixth meeting of the Committee, in which a single group of substances was discussed, should be repeated.

### **GENERAL**

The Committee was of the opinion that in future all requests from various organizations for the establishment of international biological standards, reference preparations, and reference reagents should be channelled through the World Health Organization. The Committee considered that priority should be given to substances used in prophylaxis, therapy or diagnosis of human diseases and for which, by use of international standards and reference preparations, a designation of activity could be made in quantitative terms. There may be occasions, however, when the Committee will have to consider biological reference reagents for use in qualitative procedures, and for which the assignment of a unit of measurement is not applicable. In such cases a careful selection will have to be made of those substances that could serve as international reference reagents on the basis of their need and value in diagnosis. On the other hand, the Committee considered that the establishment of standards, reference preparations or reference reagents for biological substances used only for research purposes should not be the concern of the Committee.

There are also occasions when WHO technical units ask the Committee to give international recognition to certain biological materials which those units have themselves obtained and investigated. Previous examples of such occasions are the diagnostic sera for viruses and lepto-

spires. The Committee considered that this was a valuable service and one that should be continued in future. The biological substances concerned must be of the high quality required by the Committee.

The Committee was of the opinion that its work should continue to advance on a broad front and where a special subject called for treatment in depth this could be done by holding a workshop prior to a meeting of the Expert Committee. As a result of such a workshop, the formulation of requirements and the establishment of international standards, reference preparations, or reference reagents could be recommended to the Expert Committee. The Committee agreed that such a procedure might be adopted in the case of blood products and related substances before its next meeting. The Committee concluded, therefore, that the procedure followed at its twenty-sixth meeting of devoting the whole agenda to a single special subject should not be repeated.

## SUBSTANCES

### ANTIBIOTICS

#### 1. Doxycycline

The Committee noted the results<sup>1</sup> of the collaborative study referred to in its twenty-fourth report.<sup>2</sup> The Committee also noted that in accordance with the authorization in its twenty-fifth report<sup>3</sup> the National Institute for Biological Standards and Control, London, on the basis of the results of the collaborative assay had established the International Reference Preparation of Doxycycline and with the agreement of the participants in the collaborative assay had defined the International Unit for Doxycycline as the activity contained in 0.0011494 mg of the International Reference Preparation of Doxycycline.

#### 2. Neomycin

The Committee noted the results<sup>4</sup> of the collaborative study of the proposed second International Reference Preparation of Neomycin. The Committee also noted that in accordance with the authorization in its

<sup>1</sup> Unpublished working document WHO/BS/75.1099.

<sup>2</sup> WHO Technical Report Series, No. 486, 1972, p. 9.

<sup>3</sup> WHO Technical Report Series, No. 530, 1973, p. 5.

<sup>4</sup> Unpublished working document WHO/BS/75.1097.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30847](https://www.yunbaogao.cn/report/index/report?reportId=5_30847)

